Evidence map›Paper›PMID 32529543›Full record

ArticleCellular and molecular neurobiology2021

LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.

Xin He, Jie Sheng, Wei Yu, Kejian Wang, Shujuan Zhu, Qian Liu

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Expression of MIR155HG, LOC283856, KIAA0125, and LOC100190986 as potential prognostic and predictive biomarkers for breast cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. PTBP1 as a potential regulator of disease.Molecular and cellular biochemistry · 2024
    Review
  11. The recruitment of CD8Cell death discovery · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xin HeInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Jie ShengInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Wei YuInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Kejian WangInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Shujuan ZhuInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Qian LiuInstitute of Neuroscience, Chongqing Medical University, Chongqing, China. qianliu@cqmu.edu.cn.ORCID http://orcid.org/0000-0001-8686-3971
Chongqing Medical University · CN

Funding

Chongqing Science and Technology Commission #cstc2015jcyjA10007National Natural Science Foundation of China #81502161
6 · The paper itself

Abstract

Temozolomide (TMZ) is widely used for glioma therapy in the clinic. Currently, the development of TMZ resistance has largely led to poor prognosis. However, very little is understood about the role of MIR155HG, as a long noncoding RNA, in TMZ resistance. In our study, MIR155HG level was markedly higher in glioma patients than in normal controls and that poor survival was positively correlated with MIR155HG expression. It was apparent that TMZ sensitivity was promoted by downregulation of MIR155HG, and this could be reversed by MIR155HG overexpression in vivo and in vitro. Furthermore, polypyrimidine tract binding protein 1 (PTBP1) was proven to bind with MIR155HG and to regulate MIR155HG-related TMZ resistance. Mechanistic investigation showed that the expression levels of both MIR155HG and PTBP1 influenced the expression of relevant proteins in the Wnt/β-catenin pathway. Collectively, the study demonstrated that the knockdown of MIR155HG increased glioma sensitivity to TMZ by inhibiting Wnt/β-catenin pathway activation via potently downregulating PTBP1.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingBrain NeoplasmsCell Line, TumorDrug Resistance, NeoplasmGliomaHeterogeneous-Nuclear RibonucleoproteinsMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsPolypyrimidine Tract-Binding ProteinProtein BindingTemozolomideWnt Signaling PathwayAntineoplastic Agents, AlkylatingHeterogeneous-Nuclear RibonucleoproteinsMicroRNAsMirn155 microRNA, mousePolypyrimidine Tract-Binding ProteinPtbp1 protein, mouseTemozolomideDrug resistanceGliomaMIR155HGPTBP1Wnt/β-catenin

Identifiers

PMID32529543
PMCPMC11448642
OpenAlexW3034626525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.